Related references
Note: Only part of the references are listed.Soluble AXL as a marker of disease progression and survival in melanoma
Karine Flem-Karlsen et al.
PLOS ONE (2020)
AXL as a Target in Breast Cancer Therapy
Sierra A. Colavito
JOURNAL OF ONCOLOGY (2020)
AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer
Nellie K. McDaniel et al.
CLINICAL CANCER RESEARCH (2020)
Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment
Mai Tanaka et al.
CANCERS (2020)
Pediatric high-grade glioma: aberrant epigenetics and kinase signaling define emerging therapeutic opportunities
Yusha Sun et al.
JOURNAL OF NEURO-ONCOLOGY (2020)
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer
Claudia Cardone et al.
EUROPEAN JOURNAL OF CANCER (2020)
Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature
Salvatore Grisanti et al.
JOURNAL OF NEUROSURGICAL SCIENCES (2019)
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
Giuseppe Lombardi et al.
LANCET ONCOLOGY (2019)
EGFR heterogeneity and implications for therapeutic intervention in glioblastoma
Eskil Eskilsson et al.
NEURO-ONCOLOGY (2018)
Dynamics of Axl Receptor Shedding in Hepatocellular Carcinoma and Its Implication for Theranostics
Elisa Holstein et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer
Miles A. Miller et al.
CLINICAL CANCER RESEARCH (2017)
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Phospho-AXL is widely expressed in glioblastoma and associated with significant shorter overall survival
Julia Onken et al.
ONCOTARGET (2017)
AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective
Samuel H. Myers et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
L. Zhou et al.
ONCOGENE (2016)
Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells
Chun-Yu Cho et al.
RNA (2016)
Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy
Maurizio Scaltriti et al.
CLINICAL CANCER RESEARCH (2016)
The impact of hypoxia and its modification of the outcome of radiotherapy
Michael R. Horsman et al.
JOURNAL OF RADIATION RESEARCH (2016)
MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation
Bishuang Cai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Reprogramming the immunological microenvironment through radiation and targeting Axl
Todd A. Aguilera et al.
NATURE COMMUNICATIONS (2016)
Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance
Miles A. Miller et al.
CANCER DISCOVERY (2016)
Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo
Julia Onken et al.
ONCOTARGET (2016)
Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells
Mikaella Vouri et al.
ONCOTARGET (2015)
Radiation promotes malignant progression of glioma cells through HIF-1alpha stabilization
Young-Heon Kim et al.
CANCER LETTERS (2014)
The Role of Factor Inhibiting HIF (FIH-1) in Inhibiting HIF-1 Transcriptional Activity in Glioblastoma Multiforme
Enfeng Wang et al.
PLOS ONE (2014)
ABL Regulation by AXL Promotes Cisplatin Resistance in Esophageal Cancer
Jun Hong et al.
CANCER RESEARCH (2013)
The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells
Aaron S. Meyer et al.
SCIENCE SIGNALING (2013)
Axl-dependent signalling: a clinical update
Vyacheslav A. Korshunov
CLINICAL SCIENCE (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
Proteolytic Cleavage of Notch: HIT and RUN
G. van Tetering et al.
CURRENT MOLECULAR MEDICINE (2011)
Caffeine Confers Radiosensitization of PTEN-Deficient Malignant Glioma Cells by Enhancing Ionizing Radiation-Induced G1 Arrest and Negatively Regulating Akt Phosphorylation
Brigitte Sinn et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells
Zhizhong Li et al.
CANCER CELL (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Axl and growth arrest - Specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme
Markus Hutterer et al.
CLINICAL CANCER RESEARCH (2008)
Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival
P Vajkoczy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)